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1. INTRODUCTION {#brb3946-sec-0005}
===============

Glycosylated hemoglobinA1c (HbA1c) reflects the average fasting and postprandial blood glucose over a period of 2 to 3 months and is clinically used to evaluate diabetes control (Egoldstein, [2004](#brb3946-bib-0008){ref-type="ref"}). During hospitalization, HbA1c was useful to identify undiagnosed diabetes mellitus (DM) and prediabetes, regardless of the specific blood glucose in acute ischemic stroke (Roquer et al., [2014](#brb3946-bib-0022){ref-type="ref"}).

Caplan suggested that intracranial branch atheromatous disease (BAD) was the fourth etiological factor of small deep cerebral infarction (Caplan, [1989](#brb3946-bib-0006){ref-type="ref"}). It is a common stroke subtype of Asian populations and has drawn more and more attention in recent years. BAD is caused by atherosclerotic plaques that make the orifice of larger caliber penetrating arteries narrow or occlusive (Fisher, [1979](#brb3946-bib-0009){ref-type="ref"}; Terai, Hori, Tamaki, & Saishoji, [2000](#brb3946-bib-0025){ref-type="ref"}). Intracranial BAD was divided into two different types: paramedian pontine arteries (PPA) disease (PPD) and lenticulostriate arteries (LSA) disease. Small deep cerebral infarctions are usually caused by two different pathological changes of arteries: BAD and lipohyalinotic degeneration (LD), which is mainly caused by lipid degeneration in the process of penetrating arteries (Baumgartner, Sidler, Mosso, & Georgiadis, [2003](#brb3946-bib-0004){ref-type="ref"}; Caplan, [1989](#brb3946-bib-0006){ref-type="ref"}).

Previous study showed that HbA1c was not correlated with the risk for various subtypes of ischemic stroke (Heo, Lee, Kim, Kang, & Yoon, [2010](#brb3946-bib-0010){ref-type="ref"}). Furthermore, our previous study, which represented all of acute ischemic stroke patients, showed that DM or HbA1c was not significantly related to progression and poor outcome of BAD (Men, Li, et al., [2013](#brb3946-bib-0018){ref-type="ref"}; Men, Wu, et al., [2013](#brb3946-bib-0019){ref-type="ref"}). However, Ichikawa et al. ([2010](#brb3946-bib-0012){ref-type="ref"}, [2012](#brb3946-bib-0011){ref-type="ref"}) found DM had an independent association with the development of brainstem infarctions and higher HbA1c levels were independently correlated with the basilar artery/internal carotid artery ratio, which indicated that DM has different effects on anterior and posterior circulation (Ichikawa et al., [2009](#brb3946-bib-0013){ref-type="ref"}). Some studies concluded that BAD often results in fluctuations and progression of the disease (Bassetti, Bogousslavsky, & Barth, [1996](#brb3946-bib-0003){ref-type="ref"}; Kaps, Klostermann, Wessel, & Bruckmann, [1997](#brb3946-bib-0014){ref-type="ref"}). Although it was reported that various factors are associated with the progression of BAD (Yamamoto et al., [2011](#brb3946-bib-0027){ref-type="ref"}), the correlation between HbA1c and PPD or its prognosis was not discussed in those studies. We wondered whether HbA1c might influence only a type of BAD, such as PPD. To identify the traditional vascular risk factors that have different effects on PPD, we conducted a clinical and radiological investigation of the relationship of HbA1c levels with Chinese patients with PPD and evaluated whether HbA1c may be an independent risk factor for PPD vasculopathy and its prognosis.

2. METHODS {#brb3946-sec-0006}
==========

2.1. Patient selection {#brb3946-sec-0007}
----------------------

Between January 2008 and August 2015, 354 consecutive patients with a first‐ever acute brainstem infarctions, who had symptom onset within 7 days, were collected in the Department of Neurology of The Third Affiliated Hospital of Sun Yat‐sen University. We excluded patients who were seriously infected and whose stroke subtype was large artery disease (*n* = 100), cardio‐embolism (*n* = 16), and other determined or undetermined origin (*n* = 29). At admission, HbA1c was examined to exclude patients without laboratory data from HbA1c (*n* = 20) or lost during follow‐up (*n* = 30). Therefore, a total of 159 patients were eventually enrolled. The Hospital institutional review board approved this study (No. 2011‐2‐48). Patients or families signed informed consent. For research purposes, researchers record the patient\'s examination scores and standard laboratory test results.

2.2. Diagnosis of ischemic stroke subtype by MRI {#brb3946-sec-0008}
------------------------------------------------

Small deep cerebral infarctions are usually caused by the two different pathological changes of arteries: 1. BAD and 2. LD. The diagnosis of BAD is based on radiological findings and previous reports (Yamamoto et al., [2011](#brb3946-bib-0027){ref-type="ref"}), defined as follows: the BAD of LSA is cerebral infarction with a diameter greater than 15 mm and three or more lesions are seen in axial slices, and PPA is defined as a unilateral infarction that extends to the basal surface of the pons (Figure [1](#brb3946-fig-0001){ref-type="fig"}). The PPA irrigates the medial and lateral parts, and the medial wall of the corticospinal tract, which includes anteromedial and anterolateral pontine arteries. We attempted to discriminate BAD, which is presumed to be caused atherosclerotic lesions of penetrating arteries of larger caliber at its orifices or proximal part, from LD (Figure [2](#brb3946-fig-0002){ref-type="fig"}), which is thought to result from lipohyalinosis of penetrating arteries (Baumgartner et al., [2003](#brb3946-bib-0004){ref-type="ref"}). We only selected BAD in PPA territory to study, which was known as PPD.

![Images of paramedianpontine arteries disease](BRB3-8-e00946-g001){#brb3946-fig-0001}

![Images of lipohyalinotic degeneration(LD) in the pons](BRB3-8-e00946-g002){#brb3946-fig-0002}

We classified other infarcts as LD in pontine arteries territory based on the clinicoanatomic correlations in patients with stroke (Men, Li, et al., [2013](#brb3946-bib-0018){ref-type="ref"}; Tatu, Moulin, Bogousslavsky, & Duvernoy, [1998](#brb3946-bib-0024){ref-type="ref"}). Tatu et al. ([1998](#brb3946-bib-0024){ref-type="ref"}) used a map to determine the infarcts of the PPA territory based on arterial territory definition. Some patients deteriorate within 3 days of stroke onset and stroke radiological findings usually do not stabilize until approximately 3 days after onset. We performed two MRIs for each selected patient within 3 days and made the final diagnosis based on the second MRI.

2.3. Clinical information and assessment {#brb3946-sec-0009}
----------------------------------------

Following risk factors or comorbid conditions were recorded: age, gender, hypertension, previous cerebrovascular accident (PCA), DM (defined as receiving diabetes medication, fasting glucose (FG) ≥126 mg/dl or 2 hr postprandial blood glucose≥200 mg/dl after achieving stable medical and neurological status) dyslipidemia, coronary artery disease (CAD), and smoking (\>10 cigarettes/day). Hypertension was defined as follows: previously diagnosed, including blood pressure examinations from the last year, newly diagnosed (≥ 160/90 mmHg) at time of discharge or at least 1 week of hospital care, or current treatment during the last 2 weeks before stroke onset. Dyslipidemia was defined as follows: previously diagnosis, receiving cholesterol‐reducing agents, or newly diagnosis with fasting serum total cholesterol\>240 mg/dl. CAD was defined as follows: patients with known angina or myocardial infarction. Clinical and laboratory data were collected from these adult individuals. To know kidney function, we used the estimated glomerular filtration rate (eGFR) equation to estimate glomerular filtration rate (GFR) by serum creatinine (S‐Cr) and age: eGFR (ml/min per 1.73 m^3^) = 194 ×  age ^−\ 0.287^ × S‐Cr ^−\ 1.094^ (if female × 0.739) (Ichikawa et al., [2009](#brb3946-bib-0013){ref-type="ref"}).

The National Institutes of Health Stroke Scale (NIHSS) scores at hospital admission were assessed immediately prior to MRI scans (Caplan, [1989](#brb3946-bib-0006){ref-type="ref"}). Next, we assessed the clinical outcome using a modified Rankin scale (mRS) score at 6 months (± 1 week) after the onset of the acute stroke (van Swieten, Koudstaal, Visser, Schouten, & van Gijn, [1988](#brb3946-bib-0023){ref-type="ref"}). We further divided patients with PPD into two groups with follow‐up mRS (FmRS) scores of \>2 and ≤2. A mRS score of 6 was used for patients who died during the study period. Patients with FmRS ≤2 were considered to have a good outcome; patients with FmRS \> 2 were considered to have a bad outcome (Bassetti et al., [1996](#brb3946-bib-0003){ref-type="ref"}) in PPD. Six months after stroke is the period for most functional recovery and is considered to be appropriate for assessing the outcome (Duncan, Jorgensen, & Wade, [2000](#brb3946-bib-0007){ref-type="ref"}). The factors described above were again compared between two groups.

MR images were obtained within 48 h of admission on a 1.5‐T whole‐body imager system (Signa; GE Medical Systems, Milwaukee, WI, USA). Intracranial vertebra‐basilar atherosclerotic diseases were assessed on MRA. Color‐coded Duplex sonography was used to detect intracranial carotid artery and vertebral artery stenosis.

2.4. Statistical analysis {#brb3946-sec-0010}
-------------------------

Differences in continuous variables among groups were analyzed with Student *t* test or Kruskal--Wallis rank sum test. The χ^2^ test or Fisher exact test were used for categorical variables, as appropriate. Two‐tailed *p* values \<.05 were subjected to logistic regression analyses. Multivariate analysis was used to adjust for determining risk factors and prognosis for PPD. The 95% confidence intervals (CI) were calculated, and *p* \< .05 was considered statistically significant. Results were expressed as odds ratios (OR) and OR \> 1.0 in bivariate analysis were chosen into multiple logistic regression analysis. The processing of data, including statistical calculations and preparing of tables, was made using the SPSS software version 16.

3. RESULTS {#brb3946-sec-0011}
==========

3.1. Comparison of clinical characteristics in PPD and LD {#brb3946-sec-0012}
---------------------------------------------------------

The baseline characteristics for the two groups (PPD and LD) are listed in Table [1](#brb3946-tbl-0001){ref-type="table-wrap"}. According to the second MRI, 75 patients were defined as PPD and 84 as LD. Patients enrolled included 97 men (61.0%) and 62 women (39.0%) with ages ranging from 40 to 95. The median score of NIHSS was 5 (interquartile range \[IQR\], 3--7) with an average at 5.36 ± 3.15. Among the 159 patients, 135 (84.9%) had hypertension, 74 (46.5%) had hyperlipidemia, 81 (50.9%) had DM, 30 (18.9%) were currently smoking, 46 (28.9%) had PCA, and 19 (11.9%) had CAD. 45 (28.3%) had basilar artery stenosis on MRA. In both groups, the initial NIHSS scores and poor outcomes at 6 months after acute stroke in the PPD group were significantly higher than those in the LD group (*p* \< .05). Comparison between PPD and LD showed a statistically significant difference in FG, HbA1c, eGFR, and uric acid (*p* = .011, *p* = .005, *p* = .027, and *p* = .018, respectively; Table [1](#brb3946-tbl-0001){ref-type="table-wrap"}).

###### 

Comparison of clinical characteristics in PPD and LD

  Characteristics                     All patients *N* = 159   PPD *N* = 75      LD *N* = 84      *p*
  ----------------------------------- ------------------------ ----------------- ---------------- -----------------------------------------------
  Age, (year)                         65.91 ± 10.99            66.04 ± 11.60     65.79 ± 10.47    .885
  Gender, male, no.(%)                97 (61.0)                44 (58.7)         53 (63.1)        .568
  Risk factors, no.(%)                                                                            
  Hypertension                        135 (84.9)               63 (84.0)         72 (85.7)        .763
  Diabetes mellitus                   81 (50.9)                41 (54.7)         40 (47.6)        .375
  Dyslipidemia                        74 (46.5)                40 (53.3)         34 (40.5)        .105
  Cigarette smoking                   30 (18.9)                13 (17.3)         17 (20.2)        .640
  Coronary artery disease             19 (11.9)                10 (13.3)         9 (10.7)         .611
  Previous cerebrovascular accident   46 (28.9)                20 (26.7)         26 (31.0)        .552
  Basilar artery stenosis             45 (28.3)                32 (42.7)         13 (15.5)        .000[\*\*](#brb3946-note-0003){ref-type="fn"}
  Initial NIHSS                       5.36 ± 3.15              6.64 ± 3.55       4.21 ± 2.20      .000[\*\*](#brb3946-note-0003){ref-type="fn"}
  FmRS(\>2 at 6 month after ictus)    36 (22.6)                27 (36.0)         9 (10.7)         .000[\*\*](#brb3946-note-0003){ref-type="fn"}
  Laboratory findings, mean ± SD                                                                  
  Systolic pressure                   159.59 ± 23.46           158.79 ± 22.53    160.31 ± 24.38   .684
  Diastolic pressure                  85.22 ± 13.29            83.73 ± 14.16     86.55 ± 12.39    .183
  LDLC                                3.41 ± 0.99              3.43 ± 0.95       3.39 ± 1.04      .632
  HDLC                                1.11 ± 0.26              1.11 ± 0.27       1.12 ± 0.25      .844
  TC                                  5.13 ± 1.38              5.28 ± 1.68       4.99 ± 1.04      .258
  TG                                  2.11 ± 1.69              2.25 ± 2.18       1.99 ± 1.07      .445
  ApolipoproteinB                     1.04 ± 0.30              1.08 ± 0.33       1.02 ± 0.26      .523
  ApolipopretoinA‐1                   1.32 ± 0.26              1.32 ± 0.26       1.33 ± 0.25      .909
  FG                                  6.56 ± 2.23              7.02 ± 2.30       6.13 ± 2.10      .011[\*](#brb3946-note-0003){ref-type="fn"}
  HbA1C, (%)                          6.86 ± 1.92              7.31 ± 2.11       6.46 ± 1.65      .005[\*\*](#brb3946-note-0003){ref-type="fn"}
  eGFR                                0.51 ± 0.14              0.54 ± 0.16       0.49 ± 0.13      .027[\*](#brb3946-note-0003){ref-type="fn"}
  Uric acid                           341.88 ± 99.60           322.05 ± 101.29   359.59 ± 95.20   .018[\*](#brb3946-note-0003){ref-type="fn"}
  Fibrinogen                          3.75 ± 1.02              3.68 ± 1.24       4.28 ± 4.91      .464
  Homocysteine                        13.08 ± 4.37             12.50 ± 3.80      13.60 ± 4.80     .112

eGFR, estimated glomerular filtration rate; FG, fasting glucose; FmRS, follow‐up modified Rankin Scale scores; HbA1C, hemoglobinA1c; HDLC, high‐density lipoprotein cholesterol; LD, lipohyalinotic degeneration; LDLC, low‐density lipoprotein cholesterol; NIHSS, National Institutes of Health Stroke Scale; PPD, paramedian pontine arteries disease; TC, Total cholesterol; TG, triglyceride.

\**p* \< .05; \*\**p* \< .01.

John Wiley & Sons, Ltd

3.2. Comparison of clinical information between two groups divided by FmRS scores in PPD {#brb3946-sec-0013}
----------------------------------------------------------------------------------------

The differences in HbA1c, FG, Homocysteine, eGFR, and the occurrence of DM were statistically significant between the two groups established according to the stratification of FmRS scores. The patients with PPD in poor outcome group had increased frequency in DM (*p* = .011) and higher FG (*p* = .007), Homocysteine (*p* = .038), HbA1c (*p* = .016), and lower eGFR (*p* = .037) levels as compared to those in good outcome group (Table [2](#brb3946-tbl-0002){ref-type="table-wrap"}).

###### 

Comparison of clinical information between two groups divided by FmRS scores in PPD

  Variables                           Good outcome group (*N* = 48) mRS ≤2   Poor outcome group (*N* = 27) mRS \>2   *p*
  ----------------------------------- -------------------------------------- --------------------------------------- -----------------------------------------------
  Age, (year)                         65.15 ± 10.58                          67.63 ± 13.29                           .377
  Gender, male, no. (%)               29 (60.4)                              15 (55.6)                               .682
  Risk factors, no. (%)                                                                                              
  Hypertension                        41 (85.4)                              22 (81.5)                               .746
  Diabetes Mellitus                   21 (43.8)                              20 (74.1)                               .011[\*](#brb3946-note-0005){ref-type="fn"}
  Dyslipidemia                        27 (56.2)                              13 (48.1)                               .500
  Cigarette smoking                   9 (18.8)                               4 (14.8)                                .759
  Coronary artery disease             4 (8.3)                                6 (22.2)                                .154
  Previous cerebrovascular accident   11 (22.9)                              9 (33.3)                                .327
  Basilar artery stenosis             21 (43.8)                              11 (40.7)                               .800
  Initial NIHSS                       5.00 ± 2.12                            9.56 ± 3.72                             .000[\*\*](#brb3946-note-0005){ref-type="fn"}
  Laboratory findings, mean±*SD*                                                                                     
  Systolic pressure                   156.98 ± 22.88                         162.00 ± 21.95                          .358
  Diastolic pressure                  82.85 ± 12.32                          85.30 ± 17.09                           .517
  LDLC                                3.42 ± 0.98                            3.44 ± 0.91                             .942
  HDLC                                1.10 ± 0.23                            1.12 ± 0.34                             .728
  TC                                  5.01 ± 1.19                            5.75 ± 2.27                             .077
  TG                                  2.13 ± 0.97                            2.45 ± 3.43                             .212
  ApolipoproteinB                     1.05 ± 0.28                            1.12 ± 0.40                             .732
  ApolipoproteinA‐1                   1.35 ± 0.27                            1.25 ± 0.24                             .105
  FG                                  6.43 ± 1.82                            8.09 ± 2.68                             .007[\*\*](#brb3946-note-0005){ref-type="fn"}
  HbA1C, (%)                          6.67 ± 1.19                            8.45 ± 2.82                             .011[\*](#brb3946-note-0005){ref-type="fn"}
  eGFR                                0.51 ± 0.16                            0.59 ± 0.15                             .037[\*](#brb3946-note-0005){ref-type="fn"}
  Uric acid                           339.91 ± 103.60                        290.29 ± 90.35                          .056
  Fibrinogen                          3.56 ± 0.80                            4.03 ± 1.60                             .210
  Homocysteine                        13.17 ± 3.73                           11.29 ± 3.66                            .038[\*](#brb3946-note-0005){ref-type="fn"}

eGFR, estimated glomerular filtration rate; FG, fasting glucose; FmRS, follow‐up modified Rankin Scale scores; HbA1C, hemoglobinA1c; HDLC, high‐density lipoprotein cholesterol; LDLC, low‐density lipoprotein cholesterol; NIHSS, National Institutes of Health Stroke Scale; PPD, paramedian pontine arteries disease; TC, Total cholesterol; TG, triglyceride.

\**p* \< .05; \*\**p* \< .01.

John Wiley & Sons, Ltd

3.3. Logistic regression model to identify the independent predictors for the risk factors and prognosis for PPD {#brb3946-sec-0014}
----------------------------------------------------------------------------------------------------------------

Logistic regression analyses were employed to estimate the risk factors associated with PPD (Table [3](#brb3946-tbl-0003){ref-type="table-wrap"}), according to the differences significantly between PPD and LD, also those in prognosis of PPD after adjusting for confounders including eGFR, FG, Homocysteine, and HbA1c (HbA1c instead of prevalence of DM).

###### 

Logistic regression analysis for the associated risk factors and prognosis of PPD

  Parameters            Bivariate analyses   *p*              Multivariate analyses   *p*                       
  --------------------- -------------------- ---------------- ----------------------- -------- ---------------- ------
  Risk factors Of PPD                                                                                           
  FG                    1.208                1.039--1.405     .014                                              
  HbA1C, (%)            1.280                1.066--1.537     .008                    1.256    1.043--1.513     .016
  eGFR                  13.134               1.268--136.075   .031                    9.099    0.864--95.799    .066
  Uric acid             0.996                0.993--0.999     .019                                              
  Prognosis of PPD                                                                                              
  eGFR                  28.837               1.050--791.806   .047                    21.913   0.778--617.200   .070
  HbA1C, (%)            1.561                1.184--2.058     .002                    1.546    1.167--2.049     .002
  FG                    1.397                1.108--1.761     .005                                              
  Homocysteine          0.869                0.758--0.996     .044                                              

CI,confidence interval; eGFR, estimated glomerular filtration rate; FG, fasting glucose; FmRS, follow‐up modified Rankin Scale scores; HbA1C, hemoglobinA1c; NIHSS, NIH stroke scale; OR, odd ratio; PPD, paramedian pontine arteries disease.

John Wiley & Sons, Ltd

Only HbA1c (OR=1.256, *p* = .016) was an independent predictor for the occurrence of PPD. In addition, the HbA1c was independently associated with poor outcome Of PPD (OR=1.546, *p* = .002).

4. DISCUSSION {#brb3946-sec-0015}
=============

Risk factors and progressive motor deficits of all BAD have been widely researched. However, few studies have focused on prognosis of BAD in PPA territory and the risk factors of BAD in the territory, compared to LD. In this study, higher HbA1c level is strongly correlated with BAD in PPA territory, suggesting the potential involvement of HbA1c in the pathogenesis of BAD in PPA territory, compared to LD. It is to our knowledge that our study is the first time to show the correlation of Hb1Ac level change with the prognosis of BAD in PPA territory, compared to other risk factors.

HbA1c measurement is now widely used to monitor chronic hyperglycemia (Barr, Nathan, Meigs, & Singer, [2002](#brb3946-bib-0002){ref-type="ref"}). Moreover, HbA1c determination was used to identify new DM cases and could be useful not only for the diagnosis of DM in patients with acute hyperglycemia, but also for discovering DM in those with acute stroke at normal glucose levels (Roquer et al., [2014](#brb3946-bib-0022){ref-type="ref"}).

Some previous studies have shown that DM is associated with cerebral small vessel disease (CSVD) (Kloppenborg, Nederkoorn, Graaf, & Geerlings, [2011](#brb3946-bib-0016){ref-type="ref"}). A recent major study has shown that DM is correlated with specific patterns of stroke type, etiology, and topography and has a higher incidence of subcortical infarcts and more frequent effects on posterior circulation regions (Uluduz, Ince, & Bozluolcay, [2005](#brb3946-bib-0026){ref-type="ref"}). Previous neuropathological studies demonstrated that a high incidence of subcortical infarctions in patients with DM, especially in the pons perfused by PPA (Baumgartner et al., [2003](#brb3946-bib-0004){ref-type="ref"}; Terai et al, [2000](#brb3946-bib-0025){ref-type="ref"}). A recent study showed that branch occlusion was a more important mechanism in posterior circulation diseases (Kim et al., [2012](#brb3946-bib-0015){ref-type="ref"}). Based on these reports, this study indicated that PPD is independently associated with HbA1c, compared with LD, which represented the control of diabetes. Kunz, Griese, and Busse ([2003](#brb3946-bib-0017){ref-type="ref"}) have suggested that the main etiology of unilateral paramedian pontine infarction is BAD. Nakase, Yamamoto, Ooiwa, Hayashi, and Nakajima ([2000](#brb3946-bib-0020){ref-type="ref"}) also show that DM is associated with pontine infarction due to branch atherosclerosis, but is unrelated to the BSIs of lipid degeneration. These studies are consistent with our current findings.

Our study also showed that the poor prognosis of PPD was closely related to HbA1c, in contrast to the effect of other traditional vascular risk factors. Although the definite mechanism is unknown, pathogenetic condition and outcome of acute BAD was independently associated with HbA1c, which may indicate BAD may be an important feature in patients with DM. At first, poorly controlled DM causes autonomic neuropathy which increased the vulnerability of vertebrobasilar arteries which have less sympathetic vascular innervation, accelerates atherogenesis (Beausang‐Linder & Bill, [1981](#brb3946-bib-0005){ref-type="ref"}), and makes impairment of upstream smaller vessels more serious; secondly, the possible mechanism of progressive dyskinesia and poor prognosis with basilar artery branch disease is thought to be the reduction in perfusion caused by atherosclerotic lesions in the perforation large‐diameter penetrating arteries or from diffuse thrombus caused by atherosclerotic lesions (Bassetti et al., [1996](#brb3946-bib-0003){ref-type="ref"}). The PPA are 200--300μ min diameter and have less variation (Aronson, [1973](#brb3946-bib-0001){ref-type="ref"}). In the presence of parental atherosclerotic thrombosis, the smaller and shorter perforating vessels may be more susceptible to occlusion (Kim et al., [2012](#brb3946-bib-0015){ref-type="ref"}; Peress, Kane, & Aronson, [1973](#brb3946-bib-0021){ref-type="ref"}). Future researches are expected to explain the exact mechanism of the correlation with PPD and HbA1c. It should be noted that our study also found that PPD was associated with high relative frequency of basilar artery stenosis than LD.

There are some limitations in this study: (i) The diagnosis of BAD was actually based on the definition of radiology; (ii) Bias is inevitable in retrospective; (iii) The distinction between BAD and lacunar infarcts is not clear at all times.

Nonetheless, our major findings were that HbA1c levels were associated with BAD of the PPA and the higher levels of plasma HbA1c were strongly associated with poor prognosis of BAD in PPA territory. These results suggested that elevated HbA1c may be a more helpful serologic marker in the evaluation of pathogenetic condition and prognosis of BAD in PPA territory. With chronic exposure to raised concentration of glucose, decreased blood flow or enlarged thrombosis caused by atherosclerotic lesions, may lead to poor prognosis of BAD in the proximal penetrating artery. These findings may help in the selection of glucose management and the improvement of diabetes to prevent the progression of movement disorder or lowering the adverse prognosis of PPD.
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